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Abstract objectives In this paper we discuss the main ethical challenges related to the conduct of medicine
quality surveys and make suggestions on how to address them.
method Most evidence-based information regarding medicine quality derives from surveys.
However, existing research ethical guidelines do not provide specific guidance for medicine quality
surveys. Hence, those conducting surveys are often left wondering how to judge what counts as best
practice. A list of the main ethical challenges in the design and conduct of surveys is presented.
results and conclusions It is vital that the design and conduct of medicine quality surveys
uphold moral and ethical obligations and analyse the ethical implications and consequences of such
work. These aspects include the impact on the local availability of and access to medicines; the
confidentiality and privacy of the surveyors and the surveyed; questions as to whether outlet staff
personnel should be told they are part of a survey; the need of ethical and regulatory approvals; and
how the findings should be disseminated. Medicine quality surveys should ideally be conducted in
partnership with the relevant national Medicine Regulatory Authorities. An international, but
contextually sensitive, model of good ethical practice for such surveys is needed.
keywords ethics, poor quality, medicines, surveys, falsified and substandard medicines, counterfeit
Introduction
Medicines are of vital importance in modern health
systems, and access to quality-assured medicines is part
of the basic right to health [1, 2]. Nevertheless, poor-
quality medical products, including medicines, vaccines
and diagnostic devices, are widespread due to poor man-
ufacture (substandard medicines) or deliberate falsifica-
tion (falsified medicines) [3–13]. These jeopardise
national, regional and global attempts to improve access
to effective health care because they lead to avoidable
morbidity and mortality, waste financial resources, and
contribute to drug resistance [6, 14–22]. Since poor-qual-
ity medicines result in ‘harming’ rather than ‘curing’
patients, they violate two fundamental principles of medi-
cal ethics, i.e. ‘beneficence’ and ‘non-maleficence’ [23, 24].
Medicine quality surveys are investigations in which
medicines are collected for quality testing [25, 26]. They
are essential to obtain evidence-based understanding of the
prevalence of substandard and falsified medicines in circu-
lation and to design corrective actions. The reasons and
ethical arguments for conducting these surveys are
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legitimate [23, 24] and described in Table 1. Even though
quality surveys do not involve the participation of human
subjects in medical experiments, they may put both the sur-
veyors and the surveyed at risk. Furthermore, their results
may inform national policies and have a direct impact on
individuals and their public health. Inaccurate results due
to poor methodological procedures and/or conduct (e.g. a
insufficient sample size, incorrect sampling or the analysis
of a partial set of samples) may lead to wrong policy rec-
ommendations, posing important ethical risks that require
careful thought. It is therefore of paramount importance
that all quality surveys comply with appropriate method-
ological and ethical standards.
Nevertheless, the existing guidelines on research ethics,
such as the World Medical Association Declaration of
Helsinki [27], Nuffield Council on Bioethics [28], Bel-
mont Report [24] and the CIOMS Guidelines [23], do
not provide specific guidance on the design and conduct
of medicine quality surveys. Neither do most publications
and policies related to the ethics of medical research
[29–33] and to international Good Clinical Practices
codes [34, 35]. Thus, those conducting medicine surveys
often find themselves working in contexts where ethical
guidelines and legal contexts are unclear, ambiguous or
non-existent and are often left wondering whether ethical
and regulatory clearance is required and what the issues
are in relation to the protection of confidentiality,
informed consent, etc. No consensus guidance or opin-
ions on the ethical considerations related to medicine
quality surveys have been published. The lack of national
medicine regulations, human research protection mecha-
nisms and the poor familiarity of most ethics committees
with such surveys further complicate this issue.
The intentional manufacture of and trade in falsified
medicines is a criminal activity. The penalties associated
with such offences differ depending on the laws and regula-
tions of the country concerned. The production and trade
in substandard medicines often results from technical and
human errors, or from systematic negligence, rather than
fraud, but may also be considered an offence, usually
against national drug laws and regulations under which
the medicine regulatory authorities (MRA) operate. In
some jurisdictions, the production of substandard medici-
nes could constitute criminal negligence [36]. Although
criminality and negligence raise important legal challenges,
healthcare providers’ failure to practice in accordance with
standard of care raises important ethical questions.
As a first step to address this problem,we identify and discuss
themajor ethical issues related to the design and conduct of
medicine quality surveys.Medicine quality surveysmay be con-
ducted by diverse groups of investigators, ranging fromMRA
inspectors, pharmaceutical companies, journalists, interna-
tional organisations and academic researchers. All such groups
should behave ethically, and consider the ethical obligations
and consequences of theirwork, especially towards the pre-
dictable and unpredictable risks to those surveyed, those survey-
ing, thewider public and public health.
A comprehensive ethical analysis should consider at
least:
• The appropriateness and scientific soundness of the
survey methodology;
• The local impact on the availability of the surveyed
medicines;
• The confidentiality and privacy risks to surveyors
and the surveyed;
Table 1 Ethical arguments in favour of conducting medicine
quality surveys
Individuals and communities are harmed by taking medicines
that are ineffective or toxic, or both. Scientifically and ethically
sound surveys may help to better understand the prevalence
and causes of poor-quality medicines, and to avoid these harms
in the future
There are important public health benefits to be gained from
having accurate information about type of products, frequency
and causes of poor-quality medicines on the market in
particular locations, so that context-specific corrective measures
can be implemented
Surveys may also provide information on banned/illegal/
unregistered/unauthorised medicines which will be useful to
plan how to prevent them
Provision of information to MRAs may help identify outlets who
sell and/or manufacture falsified or substandard medicines in
subsequent MRA/police investigations
Surveys may provide information that will facilitate technical
support for improvement in the manufacturing of medicines,
for example factory re-inspections, withdrawal of importing
licences, post-marketing quality control, batch recalls, etc
The benefits to communities, health professionals and medicines
purchasers of raising awareness about poor-quality medication/
medical products and how to reduce their risk, in particular by
allowing their identification and corrective actions before they
reach patients
Appropriate dissemination of this information to prescribers and
consumers promotes the ethical principle of autonomy as it
provides information facilitating medical staff and patient0s
ability to determine the optimal sources of their medicines
The prevention of use of medicines containing low/insufficiently
bioavailable API may prevent exposure of organisms to
subtherapeutic drug levels that facilitate emergence of resistance
The preservation of already scarce financial resources that would
have been spent on poor-quality medicines
Survey findings/results may lead to improvement in government
political will and commitment towards strengthening MRA’s
capacity to perform its roles and responsibilities
Survey results may also lead to development, revision and
changes in medicines policy, especially with regard to quality
assurance of medicines
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• Whether the surveyed should be told they are part of
a survey or if/when deception is acceptable;
• Which ethical and regulatory approvals should be
obtained;
• How the data will be shared, who will share what,
with whom and when;
• How the findings should be disseminated (e.g. should
the identity of the surveyed manufactures/distributors
be disclosed in reports and publications?).
There is an urgent need for more work to be carried
out on the identification and analysis of these important
ethical questions.
The regulatory context
The ethical issues related to the collection of medicine
samples for quality testing will inevitably depend on the
context and country in which they are to be carried out
as requirements for regulatory and ethical clearance vary
between countries. Where possible, it is preferable to con-
duct medicine quality surveys in partnership with the
concerned MRAs, as they are accountable to both the
government and the public for the regulation and control
of medical products. However, if the MRA is poorly
functioning, this will not be possible [37], particularly
when surveying illegal/unregistered/unlicensed outlets.
Ethical challenges
Impact on the local availability of and access to
medicines
If investigators at small, remote outlets, sample a sub-
stantial amount of the stock of a particular medicine, the
availability of such medicines may be reduced or be at
risk, for example if a survey removed most antimalarials
in a malarious area in a distal limb of the supply chain.
Consideration should be given by the investigators to
providing quality-assured medicines in exchange for the
sample after purchase. An important related concern is
that health providers in the government sector may not
be willing to give medicines to the survey team because
their drugs have to be accurately accounted for and
should only be used for the patients with evidence of hav-
ing a certain disease (e.g. a positive malaria blood smear);
otherwise, they may be in trouble if audited.
Confidentiality and privacy risks to surveyors
The intentional production of and trade in falsified
medicines is a criminal activity, although thankfully an
unusual context for medical research. Security of survey
teams may be compromised through the inappropriate
disclosure of survey information. There are only a few
examples in the public domain of people working on
medicine quality being attacked or threatened, although
such incidents may be underreported. The most extreme
was the apparent attempted murder of the head of the
Nigerian National Agency for Food and Drug Adminis-
tration and Control, presumably related to her work
[38]. Therefore, the safety of mystery shoppers and overt
personnel involved in surveys of medicine quality must be
considered.
A mystery shopper is a person trained to visit retail
stores, disguising their true identity, to collect informa-
tion about the quality of service, or compliance with reg-
ulations or prices and services provided. In comparison
with overt shoppers, it is thought that mystery shoppers
will yield less biased information. If mystery shoppers are
members of the community in which they sample, this
may present particular problems if they are recognised.
Care should be taken in avoiding the identification of
mystery shoppers in survey reports and publications.
Mystery shoppers should ensure that any information col-
lected in the study remains confidential. A non-disclosure
agreement of identity between survey staff, their institu-
tion and the authority (such as MRAs) could be put in
place.
Formal overt inspection of the outlets by MRA
inspectors is likely to be the best option when the risk to
mystery shoppers is thought to be too significant. Pres-
sure on staff participating in the sampling, as well as cor-
ruption, should be taken into consideration during
planning.
Safety concerns of the research team will have to be
addressed if it becomes widely known that surveys are
carried out by particular institutions or individuals. This
is not a remote possibility – such information can be
accessed on the Internet. The responsibilities of institu-
tions and supervisors, and adequate training and support,
should be discussed with the MRA, the concerned ethics
committee, local authorities and the team members and
their institutions; a risk assessment should be performed
before the survey is undertaken.
Whether the surveyed should be told they are part of a
survey
There is currently very little information on whether
medicine providers who sell poor-quality medicines know
that they are of poor quality [39, 40]. Clearly, they must
have a moral and ethical responsibility to ensure that
what they sell is of good quality. Unfortunately, in much
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of the world, providers do not have the training or facili-
ties to assess the reliability of supply channels and iden-
tify poor-quality medicines, and they cannot rely on a
stringent regulatory oversight. The risks faced by those
surveyed may include:
• If overt, especially police or MRA, inspections are
noted in the community and raise suspicions of the
quality of medicines sold in an outlet, the outlet(s)
may lose income and incur reputational risk by the
community shopping elsewhere even though the
results of the inspection demonstrate that the medici-
nes supplied may be good quality.
• Outlet staff and owners selling poor-quality medici-
nes, but bought the drugs in good faith, may risk
harm, losing income or their business and bank-
ruptcy, perhaps being attacked or their medicines
being seized by the community, as has been
described [41].
• If staff in outlets selling falsified medicines inform,
or are thought to have informed, MRA or research
staff about those trading in such medicines, they
may risk harm.
• The publication (and dissemination) of results may
lead to reputational damage to specific individuals or
groups (e.g. losing confidence in manufacturers from
a given region or country).
For these reasons, data and samples from a survey
should be coded when sent for analysis, devoid of linkage
to named outlets.
The issue of deception
There is currently no consensus as to whether it is neces-
sary to inform outlet staff that their outlets are being
sampled and which sampling approach is more appropri-
ate [26].
On the one hand, an overt approach may allow the
investigator to learn more about the samples, distribu-
tion systems for medicines and what the outlet staff
know. If outlet staff are aware and anxious to avoid fal-
sified medicines, open sampling with feedback would
allow more data to be collected. It may facilitate direct
improvement in the medicine supply by positively engag-
ing with pharmaceutical retailers. If it is decided that
outlet staff should be informed, the objective of the
study/survey should be explained and the consent-seek-
ing process should take into consideration the cultural
context. Bias may arise in overt surveys as providers
may offer better quality medicines to give a favourable
impression and avoid harming relationships with the
MRA [42].
On the other hand, a mystery shopper approach
increases the probability that the samples obtained will
reflect what such a shopper would be sold in real life. This
is clearly appropriate for MRA investigations and should
also be aimed for during research surveys, as poor quality
or unregistered medicines may otherwise be concealed.
A third, compromise strategy is for outlets to be sam-
pled by mystery shoppers after being informed by the
study team on a prior visit that the survey will happen at
some point in the future and requesting consent for this
future undisclosed visit. However, this may influence the
seller’s medicine selling behaviour, resulting in an inaccu-
rate picture of the situation. Not sampling outlets that do
not consent may bias the results. Further research to
examine the various methods for addressing these issues
and to inform the development of models of good prac-
tice is needed.
What to do with the information once it has been
collated?
There is no consensus on what should be done, how and
when, for the release of public information if suspicious
medicines/medical products are found [43]. Clearly, pub-
lic health should be the primary priority, but there
remains tension between commercial interests, the need
to investigate (and investigator safety) and the need to
act quickly to safeguard public health.
It is clearly unethical and irresponsible for the
details of the stated manufacturer and other sample
details of poor-quality medicines not to be reported to
the MRA and the WHO Medical Product Alert Sys-
tem [44]. There is no point in performing the survey
if this is not done. Poor-quality samples should be
reported in a timely and appropriate manner to the
MRA and to WHO for action, for example rapid
batch recalls and public alerts. Academic research
findings should be reported to MRA and the WHO
Medical Product Alert, before submission for publica-
tion, as soon as the findings are considered valid and
confirmed. Journals should insist in their instructions
to authors that this is done. Academic research should
also be made available in the public domain, for
example in an open-access peer-reviewed scientific
paper or public repository [45].
Dissemination of findings
When there is evidence of international illicit trade in falsi-
fied medicines, the WHOMedical Product Alert System
[44] and INTERPOL are able to link countries MRAs and
police forces. The antimalarial quality scientific group at
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the WorldWide Antimalarial Resistance Network
(WWARN) compiles reports of antimalarial quality glob-
ally, and they are available online through the AQ Sur-
veyor [11, 45].
Complexities and uncertainties about the provenance
of products mean that it is important for statements
about samples to clearly state that the manufacturer’s
name and address on the product do not necessarily
reflect the actual origin. Investigators should consider
obtaining legal advice to ensure that samples are appro-
priately described in publications and reports.
The pharmaceutical companies whose ‘products’
(whether genuinely made by them or falsified by others)
were found to be poor quality should be informed of the
results, preferably by/with copy to the MRAs, and asked
for any information on prior reports. Liaison and collab-
oration should be encouraged. However, the pharmaceu-
tical industry should not make the final decision as to
whether information on poor-quality medicines is made
publicly available, as they have inherent conflict of inter-
ests [36, 43]. In the case of a company wishing to delay
reporting, or if a company delays addressing specific
requests (e.g. they could be requested to run tests on the
retained samples of a given batch), a public health risk
assessment should be performed urgently by a committee
of key stakeholders, including independent public health
and investigation experts, WHO, the relevant MRAs and
the pharmaceutical company involved – with the decision
based on public health and not on commercial concerns
[43]. The pharmaceutical industry also has the obligation
to report to the MRA any product quality defects, of
their own medicines, resulting in substandard products.
Depending on the seriousness of the error, voluntary
batch recall should be considered or, if the defect is sev-
ere, mandatory recall must take place in accordance to
the product recall procedures of the MRA. Corrective
actions should be implemented so that further such errors
are prevented through correct implementation of Good
Manufacturing Practices (GMP) and Good Distribution
Practices (GDP).
Reports of poor-quality medicines are probably more
likely to be published in comparison to surveys in which
medicine quality is found to be good. However, it is
unethical to selectively publish bad reports over good
reports as this will skew the collated data. We suggest
that there is an obligation to publish all surveys whatever
the results may be. Public alerts (by MRAs) should be
rapid as well as reach those at most risk – guided by pub-
lic health communication experts and with key messages
about what to do as well as what not to do. Public
engagement should be performed to reduce the risk of
patients stopping taking genuine medicines and the risk
that the public’s loose faith in medicines or the healthcare
system [2, 43].
In addition to the problems identified above, releasing
information may expose the research team to legal action
from the concerned company(ies), whilst not going public
may result in not protecting the community from pre-
ventable harm. Such difficulties may be especially chal-
lenging if medicine sources are government or
international agencies [7]. This is especially a problem
for distinguishing between negligence/errors in manufac-
turing (substandard) and degradation of pharmaceuticals
in the supply chain due to poor storage – these can be
hard to distinguish chemically [8], unless independent
tests are run on retained samples at the manufacturer.
Degradation due to poor pharmacy practice or distribu-
tion after manufacture is not the responsibility of the
pharmaceutical company but substandard medicines
clearly are.
These potential situations should be envisaged in the
initial protocol, and strategies defined in advance, when
possible in collaboration with the MRAs and other rele-
vant national stakeholders (e.g. national malaria or tuber-
culosis (TB) control programs).
The need for ethical and regulatory approval
Another unresolved question is whether medicine quality
surveys should be subject to review by a research ethics
committee. The WHO Standards and Operational Guid-
ance for Ethics Review of Health-Related Research with
Human Participants includes the statement, ‘relevant
authorities should ensure ethics review of health-related
research supported by an adequate legal framework’ [46].
A recent publication discusses ethical review in the context
of health systems research [47, 48].
We suggest that ethical scrutiny may be required if (i)
the survey goes beyond MRA routine surveillance, and/or
(ii) if the risk assessment shows that there is more than
minimal risk to surveyors, the surveyed or the commu-
nity, and/or (iii) if it is required by regulations in the
country(ies) where the survey is carried out. The follow-
ing steps should be considered:
• Ethical review of the survey protocol/methodology
should be considered before the survey, either with
preliminary discussion of the need for ethical review
with the Research Ethics Committees or a formal
submission in the study country(ies) and in the coun-
try of the research sponsor/coordinator [49].
• There may be circumstances in which ethical review
would not be applicable, for example, if Research
Ethics Committees in the study country(ies) do not
exist or do not review this kind of research. Ethical
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 803
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review could be performed by a qualified committee
elsewhere, either in the country of the research spon-
sor or of another research partner. The Science and
Ethical Review Group (SERG) at WHO [50, 51] has
developed guidelines for the establishment of scien-
tific and ethical review bodies.
• There may be situations where ethical approval may
prove difficult, depending on the restrictions of a
country, for example for surveys looking at the qual-
ity of abortion pills where there are laws preventing
pregnancy termination.
• Surveys should be carried out in cooperation with
the concerned MRAs when possible. Should this not
be appropriate [37] or possible, the decision to pro-
ceed without MRAs involvement and approval
should be documented and justified.
If risk assessment suggests that there are more than mini-
mal risks to either surveyors or the surveyed and/or if the
results of the study are expected to be potentially sensitive,
an ad hoc independent advisory board could be appointed.
This could include all the pertinent skills (e.g. analytical,
legal, ethical, sociological) and advise on the survey design
and conduct, the communication of results and the man-
agement of any problems/incidents during and after the
research. Such a board should be selected with due consid-
eration for potential conflict of interests, for example pub-
lic health should be the prime guide to decision-making
and none of the members should feel that embarrassing
data on poor-quality medicines should be suppressed.
Conclusions
The conduct of surveys of medicine and health product
quality is of great importance, particularly in settings –
often in low- and middle-income countries – where there
is a high likelihood of the widespread use of unsafe or
ineffective medicines with significant implications for
public health and for the safety of individual patients.
The reasons for conducting surveys are powerful, but
they also present ethical challenges requiring careful
thought that have had minimal discussion.
The level of risk acceptable by the survey team, the
responsibilities of institutions and supervisors, and ade-
quate training and support should be discussed with the
MRA, the concerned ethics committee and local authori-
ties if applicable, and the collection team members and
their institutions; a formal risk assessment should be per-
formed before the survey is undertaken and should be
annexed to the survey protocol. Those involved in sur-
veys should comply with appropriate methodological and
ethical standards.
It is preferable to conduct medicine quality surveys in
partnership with the concerned MRAs where possible. In
addition, ethical clearance in the study country and col-
laborative partnership with local partners (such as local
researchers, representative of communities, etc.) should
ensure that local requirements, challenges and needs are
taken in due account.
Results obtained from quality surveys may inform
national policies and have a direct impact on individuals
and their public health. Urgent release of information via
the MRA and WHO Medical Product Alert System
should be conducted for appropriate action. Public alerts
should be guided by public health communication experts
to avoid patients stop taking good quality medication.
All these dissemination activities should be seen as
morally required, for the well-being and protection of
affected communities.
Just as in other branches of medical research, scientific
and methodological soundness is a fundamental prerequi-
site for the ethical soundness of medicine quality surveys.
There needs to be much more interdisciplinary discussion
of these risks to build consensus on an ethical basis for
the conduct of medicine quality surveys.
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